Oral platelet glycoprotein IIb/IIIa receptor inhibitors - Part II

Clinical Cardiology

Volumn 26, Issue 9, 2003, Pages 401-406

  Cannon, Christopher P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acute coronary syndromes; Angioplasty; Antiplatelet therapy; Myocardial infarction; Platelets; Prognosis; Unstable angina

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; CROMOFIBAN; FIBRINOGEN RECEPTOR ANTAGONIST; LEFRADAFIBAN; LOTRAFIBAN; N ETHYL N [4 (4 PIPERIDINYL)BUTYRYL]GLYCYLASPARTYL 3 CYCLOHEXYLALANINAMIDE; ORBOFIBAN; ROXIFIBAN; SIBRAFIBAN; TIROFIBAN; UNCLASSIFIED DRUG; XEMILOFIBAN;

BLEEDING; CLINICAL TRIAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; HUMAN; LONG TERM CARE; META ANALYSIS; MORTALITY; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0041835834     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960260903     Document Type: Review

References (32)

1. Boersma E, Harrington RA, Moliterno DJ, White H, Théroux P, Van de Werf F, de Torbal A, Armstrong PW, Wallentin LC, Wilcox RG, Simes J, Califf RM, Topol EJ, Simoons ML: Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trials. Lancet 2002;359:189-198
2. Newby LK, Califf RM, White HD, Harrington RA, Van de Werf F, Granger CB, Simes RJ, Hasselblad V, Armstrong PW: The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events. Am J Med 2002;112:647-658
3. Cannon CP, McCabe CH, Wilcox RG, Langer A, Caspi A, Bernink P, Lopez-Sendon J, Toman J, Charlesworth A, Anders RJ, Alexander JC, Skene A, Braunwald E, for the OPUS-TIMI 16 Investigators: Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 2000;102:149-156
4. O'Neill WW, Serruys P, Knudtson M, van Es GA, Timmis GC, van der Zwaan C, Kleiman J, Gong J, Roecker EB, Dreiling R, Alexander J, Anders R, for the EXCITE Trial Investigators: Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. N Engl J Med 2000;342:1316-1324
5. The SYMPHONY Investigators: Comparison of sibrafiban with aspirin for prevention ofcardiovascular events after acute coronary syndromes: A randomised trial. Lancet 2000;355:337-345
6. Second Symphony Investigators: Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. Circulation 2001;103:1727-1733
7. Mousa SA, Khurana S, Forsythe MS: Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: Differentiation among glycoprotein IIb/IIIa antagonists. Arterioscler Thromb Vasc Biol 2000;20:1162-1167
8. Holmes MB, Sobel BE, Cannon CP, Schneider DJ: Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome. An OPUS-TIMI 16 substudy. Am J Cardiol 2000;85:491-493
9. Casey M, Fornari C, Bozovich G, Iglesias Varela ML, Mautner B, Cannon CP: Increased expression of platelet P-selectin in patients treated with oral orbofiban in the OPUS TIMI 16 study. Circulation 1999;100(suppl. 1):1-681
10. 3) inhibitors. Blood 1998;92:3240-3249
11. O'Neill WW, Serruys P, Knudtson M, van Es GA, Timmis GC, van der Zwaan C, Kleiman J, Gong J, Roecker EB, Dreiling R, Alexander J, Anders R: Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events. N Engl J Med 2000;342:1316-1324
12. Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, Feldman R, Palmeri ST, Ault K, Hamilton SA, Rothman JM, Novotny WF, Braunwald E: Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: Results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction (see comments). Circultation 1998;97:340-349
13. Hughes S: BRAVO trial stopped: Lotrafiban increases mortality. In the - heart.org ("Heartwire>News") Conceptis Technologies, 2000
14. Mousa SA, Kapil R, Mu DX: Intravenous and oral antithrombotic efficacy of the novel platelet GPIIb/IIIa antagonist roxifiban (DMF754) and its free acid form, XV459. Arterioscler Thromb Vasc Biol 1999;19:2535-2541
15. Mousa SA, Forsythe M, Bozarth J, Youssef A, Wityak J, Olson R, Sielecki T: XV454, a novel nonpeptide small-molecule platelet GIIb/IIIa antagonist with comparable platelet alpha(IIb)beta3-binding kinetics to c7E3. J Cardiovasc Pharmacol 1998;32:736-744
16. Mousa SA, Bozarth JM, Lorelli W, Forsythe MS, Thoolen MJ, Slee AM, Reilly TM, Friedman PA: Antiplatelet efficacy of XV459, a novel nonpeptide platelet GPIIb/IIIa antagonist: Comparative platelet binding profiles with c7E3. J Pharmacol Exp Ther 1998;286:1277-1284
17. Mousa SA, Bozarth J, Youssef A, Levine B: Oral antiplatelet efficacy of the platelet GPIIb/IIIa antagonist, DMP754 in non-human primates. Thromb Res 1998;89:217-225
18. Langer A, Goodman SG, Reilly TM, Mousa SA, Racanelli AL, O'Connor C, O'Neill WW, Kleiman NS, Gurbel P, Daly RN: Second generation oral IIb/IIIa receptor blockade: Phase II experience with roxifiban. J Am Coll Cardiol 2000;35(suppl. A):308A
19. Hiatt WR, Dormandy JA, Norgran L, Hirsch A, Creager M, Califf R, Murray G: Roxifiban in the prevention of ischemic events in peripheral arterial disease. Circulation 2002;106(suppl. 11):11-474
20. Giugliano RP, McCabe CH, Sequeira RF, Frey MJ, Henry TD, Piana RN, Tamby J-F, Jensen BK, Nicholas SB, Jennings LK, Wise RJ, Braunwald E. for the TIMI 15 A and 15B Investigators: First report of an intravenous and oral GP IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: Results of the TIMI 15A and 15B trials. Am Heart J 2000;140:81-93
21. Muller TH, Weisenberger H, Brickl R, Narjes H, Himmelsbach F, Krause J: Profound and sustained inhibition of platelet aggregation by fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, lefradafiban, in men. Circulation 1997;96:1130-1138
22. Akkerhuis KM, Neuhaus KL, Wilcox RG, Vahanian A, Boland JL, Hoffmann J, Baardman T, Nehmiz G, Roth U, Klootwijk AP, Deckers JW, Simoons ML: Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation: A phase II study. Eur Heart J 2000;21:2042-2055
23. Hamm CW, Heeschen C, Goldmann B, Vahanian A, Adgey J, Miguel CM, Rutsch W, Berger J, Kootstra J, Simoons ML, for the c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators: Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med 1999;340:1623-1629
24. Heeschen C, Hamm CW, Goldmann B, Deu A, Langenbrink L, White HD, for the PRISM Study Investigators: Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet 1999;354:1757-1762
25. Chew DP, Bhatt DL, Sapp S, Topol EJ: Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: A meta-analysis of phase III multicenter randomized trials. Circulation 2001;103:201-206
26. Quinn MJ, Plow EF, Topol EJ: Platelet glycoprotein IIb/IIIa inhibitors: Recognition of a two-edged sword? Circulation 2002;106:379-385
27. Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, Feldman R, Palmeri ST, Ault K, Hamilton SA, Rothman JM, Novotny WF, Braunwald E, for the TIMI 12 Investigators: A randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: Results of the TIMI 12 trial. Circulation 1998;97:340-349
28. Kereiakes DJ, Runyon JP, Kleiman NS, Higby NA, Anderson LC, Hantsbarger G, McDonald S, Anders RJ: Differential dose-response to oral xemilofiban after antecedant intravenous abciximab. Administration for complex coronary intervention. Circulation 1996;94:906-910
29. Nicholson NS, Abood NA, Panzer-Knodle SG, Frederick LG, Page JD, Salyers AK, Suleymanov OD, Szalony JA, Taite BB, Anders RJ: Orbofiban: An orally active GPIIb/IIIa platelet receptor antagonist. Med Res Rev 2001;21:211-226
30. Harrington RA, Armstrong PW, Graffagnino C, Van De Werf F, Kereiakes DJ, Sigmon KN, Card T, Joseph DM, Samuels R, Granett J, Chan R, Califf RM, Topol EJ: Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease. Circulation 2000;102:728-735
31. Serrano CV, Venturinelli M, Ramires JAF, Cannon CP, Nicolau JC: Role of oral blockade of platelet glycoprotein IIb/IIIa on neutrophil-platelet interactions in patients with acute coronary syndromes. J Am Coll Cardiol 2000;35(suppl A):343A
32. Adderley SR, Fitzgerald DJ: Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation. J Biol Chem 2000;275:5760-5766